KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 192 filers reported holding KITE PHARMA INC in Q4 2016. The put-call ratio across all filers is 2.29 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $355,257,000 | +305.6% | 1,975,735 | +133.9% | 0.14% | +251.3% |
| Q2 2017 | $87,579,000 | +139.8% | 844,776 | +81.5% | 0.04% | +116.7% |
| Q1 2017 | $36,526,000 | +33.9% | 465,360 | -23.5% | 0.02% | +28.6% |
| Q4 2016 | $27,286,000 | -50.7% | 608,508 | -38.6% | 0.01% | -46.2% |
| Q3 2016 | $55,325,000 | +100.1% | 990,426 | +79.1% | 0.03% | +85.7% |
| Q2 2016 | $27,650,000 | +26.9% | 553,000 | +16.5% | 0.01% | +16.7% |
| Q1 2016 | $21,795,000 | +13.6% | 474,736 | +52.4% | 0.01% | +33.3% |
| Q4 2015 | $19,193,000 | -29.6% | 311,487 | -36.4% | 0.01% | -18.2% |
| Q3 2015 | $27,255,000 | -35.0% | 489,479 | -28.8% | 0.01% | -38.9% |
| Q2 2015 | $41,922,000 | +69.7% | 687,591 | +60.5% | 0.02% | +63.6% |
| Q1 2015 | $24,708,000 | +294.8% | 428,360 | +294.7% | 0.01% | +450.0% |
| Q4 2014 | $6,258,000 | – | 108,517 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |